Zepbound Cognitive Function Impact: What the Evidence Shows

Does Zepbound affect thinking or memory?

Zepbound is approved to reduce excess body weight in adults with obesity, or adults with overweight plus a weight-related condition, and to treat moderate-to-severe obstructive sleep apnea in adults with obesity [1]. Cognition is not one of its indications, and the trials behind those approvals were built around weight and apnea-hypopnea index.

In SURMOUNT-1, 2,539 adults with obesity or overweight and no diabetes took tirzepatide or placebo for 72 weeks; the coprimary endpoints were percentage weight change and a weight reduction of 5% or more, and mean weight change was -20.9% at 15 mg versus -3.1% on placebo [3]. In two 52-week SURMOUNT-OSA trials, the apnea-hypopnea index fell 25.3 versus 5.3 events per hour without positive airway pressure at baseline, and 29.3 versus 5.5 with it; the key secondary endpoints covered body weight, hypoxic burden, sleep impairment, high-sensitivity C-reactive protein and systolic blood pressure [4]. Cognitive scores were not among the primary or key secondary endpoints [4].

What the Zepbound label lists

The label's Table 1 covers reactions that occurred in at least 2% of patients and more often than placebo in the pooled weight-management trials [1]. Fatigue appears at 5%, 6% and 7% on 5, 10 and 15 mg versus 3% on placebo, and dizziness at 4%, 5% and 4% versus 2%; no memory, confusion or concentration term appears in the table [1]. Nausea, the most common reaction, was 25% to 29% by dose versus 8% on placebo, and most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1].

The boxed warning is thyroid C-cell tumors in rats, with a contraindication for a personal or family history of medullary thyroid carcinoma or MEN 2 [1]. Section 5 warnings cover severe gastrointestinal reactions, acute kidney injury from volume depletion, gallbladder disease, pancreatitis, serious hypersensitivity, hypoglycemia (higher with insulin or a sulfonylurea), diabetic retinopathy complications and pulmonary aspiration during anesthesia or deep sedation [1].

Why GIP receptors in the brain get attention

Tirzepatide activates both the GIP and GLP-1 receptors [1], and the GIP receptor is expressed on pyramidal neurons in the cortex and hippocampus [2]. In a 2011 mouse study, animals with the GIP receptor gene deleted had impaired recognition memory and impaired spatial learning, impaired paired-pulse facilitation, a block of long-term potentiation in hippocampal CA1, and a large decrease in neuronal progenitor cells in the dentate gyrus, with no change in the number of young neurons [2]. That is knockout data: it shows what happens when the receptor is missing, not what tirzepatide does to memory in a person.

Does Zepbound cause brain fog?

Brain fog is not a term in the label's Table 1. The reactions tabulated at 2% or more include fatigue and dizziness but no cognitive entry [1]. Discontinuation for any adverse reaction was 4.8%, 6.3% and 6.7% on 5, 10 and 15 mg versus 3.4% on placebo, with most discontinuations early and for gastrointestinal reasons [1].

Which product the numbers describe

These figures come from trials and labeling of FDA-approved Zepbound. Compounded tirzepatide is not FDA approved and is not reviewed for safety, effectiveness or quality before marketing [5].